Las Vegas, NV -- (SBWIRE) -- 10/09/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: XOMA Corp (NASDAQ:XOMA), RadioShack Corporation (NYSE:RSH), Cumulus Media Inc (NASDAQ:CMLS), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
XOMA Corp (NASDAQ:XOMA) managed to keep its fall at -6.95% on above-normal volume of 1.97M shares. The stock settled at $4.82 after floating in a range of $4.80 to $5.35. Its latest price has reached market capitalization of $436.77 million. Its 52-week range has been $2.37 to $5.54. XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific.
Has XOMA Found The Bottom and Ready To Move Up? Find Out Here
RadioShack Corporation (NYSE:RSH) traded down on a volume of 1.94 million, lower than its standard daily volume. Shares have dropped-2.15% to $3.19. Over the last twelve months, the stock has gained 55.61% and faced a worst price of $1.90. RadioShack Corporation (RadioShack) is engaged in the retail sale of consumer electronics goods and services through its RadioShack store chain.
Has RSH Found The Bottom And Ready To Gain Momentum? Find Out Here
Cumulus Media Inc (NASDAQ:CMLS) settled -7.08% lower at $4.99 on above-normal volume of 2.08M shares during the last trading day. The stock has its 12-month high at $5.39 and 52-week low price was $2.09. It traded in a range of $4.87 to $5.42 during the last trading day. Cumulus Media Inc. owns and operates commercial radio station clusters in the United States.
Will CMLS Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was down on high volume, trading at a volume of 1.92M versus its average daily volume of 1.46 million shares. At $6.75, the stock has attained market capitalization of 393.20 million. BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases.
Why Should Investors Buy BCRX After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)